PLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Protalix BioTherapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.10.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Protalix BioTherapeutics was 59.70% per year. The lowest was -54.60% per year. And the median was 11.45% per year.
For the Biotechnology subindustry, Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Protalix BioTherapeutics (AMEX:PLX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Dror Bashan | director, officer: President and CEO | 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100 |
Eliot Forster | director | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Aharon Schwartz | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
Zvi Shmuel Ben | director | 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401 |
Dexcel Pharma Technologies Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 3060000 |
Dan Oren | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Eyal Rubin | officer: Sr. VP and CFO | C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601 |
Yaron Naos | officer: Sr. VP, Operations | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
Yael Hayon | officer: Vice President, R&D | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401 |
Zeev Bronfeld | director | 6 URI STREET, TEL AVIV L3 64954 |
Amos Bar-shalev | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
David Granot | director | 6225 NEIL ROAD, RENO NV 89511 |
Pol F Boudes | director | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Moshe Manor | officer: President & CEO | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
From GuruFocus
By PRNewswire PRNewswire • 04-27-2023
By PRNewswire PRNewswire • 02-21-2023
By PRNewswire PRNewswire • 02-24-2023
By PRNewswire PRNewswire • 11-07-2022
By PRNewswire PRNewswire • 06-08-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire PRNewswire • 01-03-2023
By PRNewswire PRNewswire • 12-04-2022
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire • 12-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.